Welcome to our dedicated page for BORA PHARMACEUTICALS CO news (Ticker: BORAY), a resource for investors and traders seeking the latest updates and insights on BORA PHARMACEUTICALS CO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BORA PHARMACEUTICALS CO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BORA PHARMACEUTICALS CO's position in the market.
Upsher-Smith (BORAY) on April 14, 2026 launched dedicated caregiver and healthcare professional websites to support KYMBEE™ (deflazacort) Tablets for Duchenne muscular dystrophy patients aged 5 and older. The sites offer prescribing guides, patient support tools and the Promise of Support® program for coverage, delivery and continuity of therapy.
Bora Pharmaceuticals (BORAY) subsidiary Upsher-Smith launched a generic Ciprofloxacin 0.3% / Dexamethasone 0.1% Otic Suspension (NDC 0832-1430-75, 7.5 mL) on April 6, 2026. The product carries an AB therapeutic equivalence code and lists the brand Ciprodex as the reference listed drug.
According to the company, IQVIA reports U.S. market sales for this combination at approximately $118 million, and Upsher-Smith positions the launch as part of a portfolio diversification strategy.
Bora Pharmaceuticals and GSK (LSE/NYSE: GSK) renewed a five-year global manufacturing agreement through 2030, a deal reported at $250 million. The renewal gives GSK access to multiple Bora sites, including a new oral solid dose facility in Maple Grove, Minnesota.
Bora will continue manufacturing more than 20 commercial product lines (over 335 individual products) at its Mississauga site, supporting infectious disease, mental health, dermatology and other therapeutic areas.